Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 2
1986 1
1991 1
1993 1
1997 1
2003 1
2004 2
2005 1
2006 1
2007 1
2011 1
2012 1
2013 1
2014 1
2015 2
2016 1
2017 2
2018 5
2019 3
2020 1
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "C1Q deficiency 1"
Page 1
Antibody-Dependent Enhancement (ADE) and the role of complement system in disease pathogenesis.
Thomas S, Smatti MK, Ouhtit A, Cyprian FS, Almaslamani MA, Thani AA, Yassine HM. Thomas S, et al. Mol Immunol. 2022 Dec;152:172-182. doi: 10.1016/j.molimm.2022.11.010. Epub 2022 Nov 10. Mol Immunol. 2022. PMID: 36371813 Free PMC article. Review.
Antibody-mediated effector functions are mainly driven by complement activation, and the first complement in the cascade is complement 1q (C1q) which binds to the virus-antibody complex. Reports say that deficiency in circulating plasma levels of C1q, an inde …
Antibody-mediated effector functions are mainly driven by complement activation, and the first complement in the cascade is complement 1q ( …
Complement activation promoted by the lectin pathway mediates C3aR-dependent sarcoma progression and immunosuppression.
Magrini E, Di Marco S, Mapelli SN, Perucchini C, Pasqualini F, Donato A, Guevara Lopez ML, Carriero R, Ponzetta A, Colombo P, Cananzi F, Supino D, Reis ES, Peano C, Inforzato A, Jaillon S, Doni A, Lambris JD, Mantovani A, Garlanda C. Magrini E, et al. Nat Cancer. 2021 Feb;2(2):218-232. doi: 10.1038/s43018-021-00173-0. Epub 2021 Feb 18. Nat Cancer. 2021. PMID: 34505065 Free PMC article.
C3(-/-), MBL1/2(-/-) and C4(-/-) mice showed reduced susceptibility to 3-methylcholanthrene sarcomagenesis and transplanted sarcomas, whereas C1q and factor B deficiency had marginal effects. Complement 3a receptor (C3aR), but not C5aR1 and C5aR2, deficiency …
C3(-/-), MBL1/2(-/-) and C4(-/-) mice showed reduced susceptibility to 3-methylcholanthrene sarcomagenesis and transplanted sarcomas, wherea …
Clinical presentation of human C1q deficiency: How much of a lupus?
Stegert M, Bock M, Trendelenburg M. Stegert M, et al. Mol Immunol. 2015 Sep;67(1):3-11. doi: 10.1016/j.molimm.2015.03.007. Epub 2015 Apr 3. Mol Immunol. 2015. PMID: 25846716 Review.
Hereditary human C1q deficiency has been well described to be associated with high susceptibility for the development of systemic lupus erythematosus (SLE). ...In this review, we performed a comprehensive search of electronic databases up to November 2014 to identif …
Hereditary human C1q deficiency has been well described to be associated with high susceptibility for the development of syste …
New C1q mutation in a Tunisian family.
Jlajla H, Sellami MK, Sfar I, Laadhar L, Zerzeri Y, Abdelmoula MS, Gorgi Y, Dridi MF, Makni S. Jlajla H, et al. Immunobiology. 2014 Mar;219(3):241-6. doi: 10.1016/j.imbio.2013.10.010. Epub 2013 Nov 6. Immunobiology. 2014. PMID: 24331529 Review.
Hereditary C1q deficiency (C1qD) is the most penetrant genetic factor predisposing to the development of lupus pathology with more than 93% of C1q deficient patients developing this autoimmune pathology throughout their life. ...Our analysis identified …
Hereditary C1q deficiency (C1qD) is the most penetrant genetic factor predisposing to the development of lupus pathology with …
Serum complement C1q level is associated with acute coronary syndrome.
Ni XN, Yan SB, Zhang K, Sai WW, Zhang QY, Ti Y, Wang ZH, Zhang W, Zheng CY, Zhong M. Ni XN, et al. Mol Immunol. 2020 Apr;120:130-135. doi: 10.1016/j.molimm.2020.02.012. Epub 2020 Feb 28. Mol Immunol. 2020. PMID: 32120180

RESULTS: The level of complement C1q in AMI group was lower significantly than control group and UA group (P < 0.05), but there was no correlation between serum complement C1q and Gensini score (beta=-0.086, P = 0.125). ...CONCLUSION: Serum complement C1q

…

RESULTS: The level of complement C1q in AMI group was lower significantly than control group and UA group (P < 0.05), but there wa

…
Hypocomplementemic urticarial vasculitis: association with chronic obstructive pulmonary disease.
Schwartz HR, McDuffie FC, Black LF, Schroeter AL, Conn DL. Schwartz HR, et al. Mayo Clin Proc. 1982 Apr;57(4):231-8. Mayo Clin Proc. 1982. PMID: 7040825 Review.
Preliminary diagnostic criteria are the presence of typical urticarial skin lesions and low levels of serum complement (all components), plus two of the following: dermal venulitis, arthritis, glomerulo-nephritis, episcleritis or uveitis, recurrent abdominal pain, and C1q …
Preliminary diagnostic criteria are the presence of typical urticarial skin lesions and low levels of serum complement (all components), plu …
Autoantibodies and lymphoproliferative diseases in acquired C1-inhibitor deficiencies.
Cicardi M, Zingale LC, Pappalardo E, Folcioni A, Agostoni A. Cicardi M, et al. Medicine (Baltimore). 2003 Jul;82(4):274-81. doi: 10.1097/01.md.0000085055.63483.09. Medicine (Baltimore). 2003. PMID: 12861105 Free article. Review.
Angioedema due to acquired C1-inhibitor (C1-INH) deficiency (also referred to as "acquired angioedema") is a rare, life-threatening disease with poorly defined etiology, therapy, and prognosis. To define the profile of acquired C1-INH deficiency and to facili …
Angioedema due to acquired C1-inhibitor (C1-INH) deficiency (also referred to as "acquired angioedema") is a rare, life-threatening d …
Tumor Cells Hijack Macrophage-Produced Complement C1q to Promote Tumor Growth.
Roumenina LT, Daugan MV, Noé R, Petitprez F, Vano YA, Sanchez-Salas R, Becht E, Meilleroux J, Clec'h BL, Giraldo NA, Merle NS, Sun CM, Verkarre V, Validire P, Selves J, Lacroix L, Delfour O, Vandenberghe I, Thuilliez C, Keddani S, Sakhi IB, Barret E, Ferré P, Corvaïa N, Passioukov A, Chetaille E, Botto M, de Reynies A, Oudard SM, Mejean A, Cathelineau X, Sautès-Fridman C, Fridman WH. Roumenina LT, et al. Cancer Immunol Res. 2019 Jul;7(7):1091-1105. doi: 10.1158/2326-6066.CIR-18-0891. Epub 2019 Jun 4. Cancer Immunol Res. 2019. PMID: 31164356 Free article.
To understand how the complement cascade is activated in ccRCC and impacts patients' clinical outcome, primary tumors from three patient cohorts (n = 106, 154, and 43), ccRCC cell lines, and tumor models in complement-deficient mice were used. High densities of cells produ …
To understand how the complement cascade is activated in ccRCC and impacts patients' clinical outcome, primary tumors from three patient coh …
Complement in the pathophysiology and diagnosis of human diseases.
Dalmasso AP. Dalmasso AP. Crit Rev Clin Lab Sci. 1986;24(2):123-83. doi: 10.3109/10408368609110272. Crit Rev Clin Lab Sci. 1986. PMID: 2971510 Review.
The description of the reaction mechanism includes: (1) activation of the classical pathway through recognition of IgG and IgM antibodies by C1q, (2) activation of the alternative pathway which is usually achieved without participation of immunoglobulins, (3) generation of …
The description of the reaction mechanism includes: (1) activation of the classical pathway through recognition of IgG and IgM antibodies by …
Leukocyte-Associated Ig-like Receptor 1 Inhibits Th1 Responses but Is Required for Natural and Induced Monocyte-Dependent Th17 Responses.
Agashe VV, Jankowska-Gan E, Keller M, Sullivan JA, Haynes LD, Kernien JF, Torrealba JR, Roenneburg D, Dart M, Colonna M, Wilkes DS, Burlingham WJ. Agashe VV, et al. J Immunol. 2018 Jul 15;201(2):772-781. doi: 10.4049/jimmunol.1701753. Epub 2018 Jun 8. J Immunol. 2018. PMID: 29884698 Free PMC article.
However, using a divalent soluble LAIR1/Fc recombinant protein to block interaction of cell surface LAIR1 with matrix collagen, we found that whereas T(h)1 responses were enhanced as predicted, T(h)17 responses were strongly inhibited. Indeed, LAIR1 on both T cells and mon …
However, using a divalent soluble LAIR1/Fc recombinant protein to block interaction of cell surface LAIR1 with matrix collagen, we found tha …
26 results